Research in a experimental and clinical significance of uPAR as a new therapeutic target molecule for diabetic nephropathy

Research Project

Project/Area Number	21591131
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Single-year Grants
Section	一般
Research Field	Metabolomics
Research Institution	Shiga University of Medical Science
Principal Investigator	ARAKI Shin-ichi 滋賀医科大学, 医学部, 助教 (80378455)
Project Period (FY)	2009 – 2011
Project Status	Completed (Fiscal Year 2011)
Budget Amount *help	¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000) Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000) Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2009: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Keywords	エネルギー / 糖質代謝異常 / 糖尿病性腎症
Research Abstract	We investigated the role of uPAR as a new therapeutic molecule for diabetic nephropathy. The uPAR knockout mice fed 60% high-fat diet for 12 weeks showed the decrease of body weight, serum insulin levels, serum leptin levels, and the expression levels of fibronectin and type IV collagen in the kidney, whereas albuminuria was not different. In the long follow-up observational study(median : 12 years) including 186 patients with type 2 diabetes, the subgroup with higher levels of serum soluble uPAR showed the higher cumulative incidence of renal dysfunction and cardiovascular events. Thus, these results suggest that uPAR associates with renal dysfunction in diabetic patients.